Weick J K, Jones S E, Grozea P N, Fabian C J, Dixon D O
Cancer Treat Rep. 1984 Jul-Aug;68(7-8):963-7.
Seventy-eight patients with Hodgkin's disease and non-Hodgkin's lymphoma who had failed prior chemotherapy or radiation therapy were treated with a combination of vindesine, carmustine, doxorubicin, and prednisone (EBAP). Outpatient therapy was administered at 21-day intervals. Complete and partial responses were seen in 32 patients (41%). The response rate was higher for Hodgkin's disease (59%) than for non-Hodgkin's lymphoma (31%). The median duration of response was 31 weeks in both groups, with a median survival of all patients of 35 weeks (responders, 122 weeks; nonresponders, 16 weeks). Myelotoxicity was greater using EBAP than in the earlier reported program with vincristine, carmustine, doxorubicin, and prednisone, and in the absence of higher response rates does not support the use of vindesine over vincristine in combination programs using nitrosoureas, anthracyclines, and prednisone.
78例先前化疗或放疗失败的霍奇金病和非霍奇金淋巴瘤患者接受了长春地辛、卡莫司汀、阿霉素和泼尼松联合治疗（EBAP）。门诊治疗每隔21天进行一次。32例患者（41%）出现完全缓解和部分缓解。霍奇金病的缓解率（59%）高于非霍奇金淋巴瘤（31%）。两组的中位缓解持续时间均为31周，所有患者的中位生存期为35周（缓解者为122周，未缓解者为16周）。与早期报道的长春新碱、卡莫司汀、阿霉素和泼尼松方案相比，使用EBAP时骨髓毒性更大，且在缓解率未提高的情况下，不支持在使用亚硝基脲类、蒽环类和泼尼松的联合方案中用长春地辛替代长春新碱。
